Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

British journal of cancer·2026
Same author

Lymph Node Sampling Patterns and Completeness of Staging During Systematic Mediastinal Lymph Node Staging in Patients with Locally Advanced Non-Small-Cell Lung Cancer: A Post Hoc Analysis from the SEISMIC Study.

Cancers·2026
Same author

Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy.

bioRxiv : the preprint server for biology·2026
Same author

Impact of Isolation Techniques on the Content of Small Extracellular Vesicles.

Journal of extracellular vesicles·2026
Same author

Unlocking beta cell health: The clinical potential of extracellular vesicles in type 1 diabetes.

Clinical and translational medicine·2026
Same author

Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.

Nature communications·2026

Related Experiment Video

Updated: Oct 7, 2025

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.3K

Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients.

Kekoolani S Visan1,2, Richard J Lobb1,3, Shu Wen Wen4

  • 1Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.

Cancers
|January 11, 2022
PubMed
Summary

Researchers identified microRNA-3182 in small extracellular vesicles (sEVs) as a potential biomarker for early non-small cell lung cancer (NSCLC) detection. This discovery could lead to earlier diagnosis and improved patient survival rates.

Keywords:
biomarkersdiagnosisexosomesextracellular vesiclesliquid biopsymiRNAnon-small cell lung cancer

More Related Videos

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K

Related Experiment Videos

Last Updated: Oct 7, 2025

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.3K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Lung cancer is a leading cause of cancer mortality globally, often diagnosed at late stages due to limited early detection methods.
  • Current diagnostic approaches like tissue biopsy and imaging are invasive and have low throughput.
  • Liquid biopsies, particularly small extracellular vesicles (sEVs), offer a non-invasive alternative for comprehensive disease information.

Purpose of the Study:

  • To validate the potential of sEVs as cancer biomarkers for non-small cell lung cancer (NSCLC).
  • To investigate the utility of specific microRNAs (miRNAs) within sEVs for early NSCLC detection.

Main Methods:

  • Characterization of cancer-derived sEVs using miRNA sequencing.
  • Comparison of miRNA expression in sEVs from NSCLC patients versus healthy controls and benign lung conditions.
  • Validation of miRNA enrichment in oncogenic versus untransformed lung cells.

Main Results:

  • microRNA-3182 (miR-3182) was found to be highly enriched in sEVs from patients with invasive breast carcinoma and NSCLC.
  • Elevated levels of sEV miR-3182 were confirmed in transformed lung cells compared to untransformed cells.
  • miR-3182 demonstrated the ability to differentiate early-stage NSCLC patients from those with benign lung conditions.

Conclusions:

  • sEV-derived miR-3182 shows significant potential as a non-invasive biomarker for early NSCLC detection in blood samples.
  • This biomarker could facilitate earlier therapeutic intervention, potentially improving patient outcomes and survival.
  • Further validation is warranted to integrate miR-3182 into clinical diagnostic workflows for NSCLC.